In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 33395331.
- Also identified by DOI 10.7326/ACPJ202101190-003.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
RECOVERY Collaborative Group. <b>Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.</b> Lancet. 2020;396:1345-52. 33031764.
Medical subject headings
- Antiviral Agents
- Hospitalization
- Lopinavir
- Ritonavir
- COVID-19 Drug Treatment